Search

Epstein-Barr virus (EBV) is an extremely successful virus, infecting more than 90% of the human population worldwide. After primary infection, the virus persists for the life of the host, usually as a harmless passenger residing in B cells. However, EBV can transform B cells, which can result in the development of malignant lymphomas. Intriguingly, the three main types of EBV-associated B-cell lymphoma - that is, Burkitt lymphoma, Hodgkin lymphoma and post-transplant lymphomas - seem to derive from germinal-centre B cells or atypical survivors of the germinal-centre reaction in most, if not all, cases, indicating that EBV-infected germinal-centre B cells are at particular risk for malignant transformation. [ABSTRACT FROM AUTHOR]

The article discusses the study that explores the relevance of intracellular free Mg(2,+) on the toxicity activity of T cells and natural killer (NK) cells. It highlights the capabilities of Mg(2,+) in controlling the expression of the activating receptor NK group 2 member D (NKG2D). It adds that the Epstein-Barr virus (EBV) has upregulated the NKG2D ligands by infecting the cells.

Highlights research findings regarding cells as of October 2005. Significance of caspase-8 for antigen-induced T-cell proliferation; Expression of killer-cell immunoglobulin-like receptor ligand in cells infected with Epstein-Barr virus; Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate in a mouse model of Alzheimer disease.

Presents summaries of several studies on psychoneuroimmunology, lymphocyte migration and viral immunity. Correlation between physiological measures of negative emotion and the immune response to an influenza vaccine; Acquisition by dendritic cells of antigens; Self-inhibition of synthesis and antigen representation by Epstein-Barr virus-encoded protein nuclear antigen 1.